Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 30;7:9974. doi: 10.1038/s41598-017-09707-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

PKA and CREB inhibitors block PTEN expression mediated by PGE1 in PTEN-silenced PASMCs. PASMCs were transfected with siRNA for PTEN or scrambled siRNA as a control non-targeting siRNA. The PTEN-silenced PASMCs were exposed to a PKA inhibitor (1, 5, or 10 μmol/L) or CREBi (0.1, 0.5, or 1 μmol/L) and incubated with or without PGE1 (100 nmol/L). Representative immunoblots of PTEN and pCREB following treatment with 100 nmol/L PGE1 was reversed with a PKA inhibitor (H89) and a CREB inhibitor (CREB i) (a, b). PTEN-induced inhibition of pAKT via treatment with 100 nmol/L PGE1 was also reversed by the PKA (H89) and CREB inhibitors (CREB i). Representative immunoblots of the H89 (c) and CREBi inhibitors (d) and densitometric quantification of protein expression following PKA (e) and CREBi inhibitor (f) treatment in PTEN-silenced PASMCs.